-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 23, the CDE official website showed that Pfizer's "Vupanorsen injection" was approved for clinical use in China for the first time.
Vupanorsen was first discovered by Ionis.
ANGPTL3 is a key regulator of triglyceride and cholesterol metabolism.
Based on its optimism about its potential, in October 2019, Pfizer, Akcea and Ionis reached an exclusive global license agreement for vupanorsen.
At the 2020 European Society of Cardiology Annual Meeting (ESC) online meeting, Akcea presented Vupanorsen's Phase 2a clinical data for the treatment of cardiovascular disease.
The trial is a randomized, double-blind, multi-center, placebo-controlled phase 2 study, enrolling 105 patients with hypertriglyceridemia, type 2 diabetes, and liver steatosis.
In the Vupanorsen 40 mg/4 weeks (Q4W) or 80 mg/4 weeks (Q4W) and 20 mg/week (QW) three cohorts, triglyceride levels were reduced by 36%, 53%, and 47%, respectively, while comfort The triglyceride of the dosage group was only reduced by 16%.
Compared with the placebo group, the Vupanorsen 80mg Q4W group reduced ANGPTL3 (62%), apolipoprotein CIII (58%), total cholesterol (19%), non-high-density lipoprotein cholesterol (18%), and high-density lipids.
At present, Pfizer has initiated phase IIb clinical trials abroad.
Antisense RNA therapy is an important area that has attracted much attention in recent years.
Novartis acquired The Medicine Company for US$9.
